Mobile

A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctiv...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017961-52

A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctive treatment in patients with partial onset seizures

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Detect a dose-response of BGG492 as measured by change in seizure frequency from the 4-week baseline period (week -4 to .1) to the 4-week double-blind maintenance period (weeks 7 to 10).

Critère d'inclusion

  • refractory partial-onset seizures

Liens